Blog

Pawel Kalinski: The use of TAAs as ubiquitous targets for adoptive T cell therapies in solid tumors

Photo taken from Pawel Kalinski/LinkedIn

Sep 3, 2024, 12:16

Pawel Kalinski: The use of TAAs as ubiquitous targets for adoptive T cell therapies in solid tumors

Pawel Kalinski, Senior Vice President for Team Science at Roswell Park Comprehensive Cancer Center, shared on LinkedIn:

“Contratulatuons to Dr. Dong for his impressive PhD thesis and for this critical contribution to our understanding of how cytotoxic lymphocytes (CTLs) can selectively recognize low levels of unmutated tumor-associated antigens (TAAs) on cancer cells, but not the same antigens expressed by healthy tissues

Best wishes for his postdoctoral research at our lab in developing a new class of T cell therapies, using dual recognition by TCR (or CAR) and NK receptors (NKRs) to allow the use of TAAs as ubiquitous targets for adoptive T cell therapies (ACT) in solid tumors.

‘NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs‘

Authors: Bowen Dong, Natasa Obermajer, Takemasa Tsuji, Junko Matsuzaki, Cindy M Bonura, Cindy Sander, Henry Withers, Mark D Long, Colin Chavel, Scott H Olejniczak, Hans Minderman, John M Kirkwood, Robert P Edwards, Walter J Storkus, Pedro Romero, Pawel Kalinski.”

Pawel Kalinski: The use of TAAs as ubiquitous targets for adoptive T cell therapies in solid tumors

Source: Pawel Kalinski/LinkedIn

Bowen Dong cancer Cindy M Bonura Cindy Sander Colin Chavel cytotoxic lymphocytes Hans Minderman Henry Withers John M. Kirkwood Junko Matsuzaki Mark D Long Natasa Obermajer NK receptors OncoDaily Oncology Pawel Kalinski Pedro Romero Robert P Edwards Scott H Olejniczak Takemasa Tsuji Walter J Storkus

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage